Rare Disease Genetic Testing Market Share To Reach Scalable Heights Of Growth

 The rare disease genetic testing market is entering a high-growth phase as healthcare providers increasingly use genomic technologies to identify inherited disorders that are difficult to diagnose through conventional methods.

AI is becoming an important technology within genomic diagnostics. AI-powered bioinformatics can analyze large genomic datasets, identify potentially disease-causing variants, improve variant interpretation, and support clinical decision-making. The integration of AI with next-generation sequencing, whole-genome sequencing, RNA analysis, and multi-omics is expected to improve diagnostic accuracy and reduce the time required to identify rare diseases.

Key Market Statistics

The global rare disease genetic testing market was valued at USD 1.3 billion in 2025 and is expected to grow to USD 3.9 billion by 2033. The estimated market size for 2026 is USD 1.5 billion, with a CAGR of 14.9% during the 2026 to 2033 forecast period.

Neurological disorders represented the largest disease segment, accounting for 29.1% of market revenue in 2025. Next-generation sequencing was the leading technology segment, holding 57.1% of the market in the same year. Molecular genetic tests represented the largest specialty segment, while diagnostic laboratories held the leading position among end-use categories.

The market is supported by the large global population affected by rare diseases. Grand View Research notes that rare diseases affect more than 300 million people worldwide, while approximately 80% of rare diseases have a genetic origin. The long diagnostic journey experienced by many patients creates significant demand for faster and more comprehensive genetic testing.

The reduction in genome sequencing costs is another important factor. Lower sequencing costs allow laboratories to process more samples while investing in automation, bioinformatics, variant interpretation, and clinical decision-support systems. These developments are making genomic testing more accessible across healthcare systems.

Download a free sample copy of the Rare Disease Genetic Testing market report to understand detailed coverage and inclusions in the final report

Market Drivers & Risks

One of the strongest drivers is the increasing adoption of next-generation sequencing. NGS allows laboratories to examine large genomic regions and identify genetic variants that may be missed through traditional testing. Whole-exome sequencing and whole-genome sequencing are particularly valuable for patients with complex or undiagnosed conditions.

Growing awareness of rare diseases is also supporting market expansion. Patient advocacy programs, disease registries, conferences, and government initiatives are increasing awareness among patients, healthcare professionals, and policymakers. Rare disease registries also provide valuable clinical and genomic information that can improve genotype-phenotype analysis and variant interpretation.

Personalized medicine is another major growth opportunity. Genetic testing can help healthcare providers understand the molecular basis of a disease and support more targeted treatment decisions. Increasing demand for precision medicine is therefore encouraging healthcare organizations to incorporate genomic testing into diagnostic workflows.

However, the market also faces several risks. Genetic testing can involve complex interpretation, especially when tests identify variants of uncertain significance. Data privacy, ethical concerns, regulatory requirements, reimbursement limitations, and shortages of specialized genomic professionals can create barriers to adoption. Regulatory requirements from authorities such as the FDA and European regulators can also increase the cost and time required to validate and commercialize testing services.

Market Breakdown and Core Segments

• The market is segmented by disease, technology, specialty, end use, and region. Neurological disorders held the largest disease segment in 2025 with a 29.1% revenue share. Endocrine and metabolism diseases are expected to be among the fastest-growing disease categories, supported by increasing diagnosis and recognition of inherited metabolic conditions.
• By technology, next-generation sequencing dominated with a 57.1% revenue share in 2025. NGS is widely used because it can analyze multiple genes simultaneously and provide broader genomic coverage than many conventional techniques. Whole-exome and whole-genome sequencing are also becoming increasingly important for difficult-to-diagnose cases.
• By specialty, molecular genetic tests accounted for the largest revenue share in 2025. Molecular testing includes approaches such as PCR, Sanger sequencing, gene panels, and NGS. Different technologies continue to have specific applications depending on the suspected disorder, genetic variant, cost, and required turnaround time.
• By end use, diagnostic laboratories represented the leading segment. The segment is benefiting from partnerships between genetic testing companies and diagnostic laboratories, increased testing volumes, and growing demand for specialized genomic services.

Looking for more specific insights? Customize this report to suite your business needs

Leading Industry Players

The competitive landscape includes diagnostic laboratories, genomic testing companies, biotechnology companies, and specialized genetic testing providers. Key companies identified by Grand View Research include Quest Diagnostics, Centogene, Invitae, 3billion, ARUP Laboratories, Eurofins Scientific, Strand Life Sciences, Ambry Genetics, PerkinElmer, REALM IDx, Macrogen, Baylor Genetics, Color Genomics, PreventionGenetics, Fulgent Genetics, Myriad Genetics, Labcorp, OPKO Health, and Artemis DNA.

Companies are increasingly competing through advanced sequencing platforms, AI-powered genomic analysis, multi-omics, laboratory automation, and strategic partnerships. For example, Ambry Genetics launched ExomeReveal, which combines exome sequencing with RNA analysis to improve rare disease detection and variant interpretation. MyOme also introduced a rare disease diagnostic product based on whole-genome analysis.

Conclusion

The rare disease genetic testing market is positioned for strong expansion as genomic technologies become more affordable, accurate, and integrated into clinical diagnostics. With the market expected to reach USD 3.9 billion by 2033, NGS, AI-driven analysis, whole-genome sequencing, RNA analysis, and multi-omics will remain important areas of innovation. North America currently leads the industry, while emerging markets are creating additional opportunities. The combination of increasing rare disease awareness, personalized medicine, declining sequencing costs, and advanced computational analysis is expected to accelerate adoption of genetic testing and improve the diagnosis of patients with rare and previously undiagnosed conditions.

Explore our dedicated business services:

• US Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.